Quick Answer
X4 Pharmaceuticals, Inc reported Research And Development Expense of $72.72 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed a decrease of -10.9% in Research And Development Expense from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $4.39 million | Q2 2017: $3.91 million | Q3 2017: $10.60 million | Q1 2018: $4.74 million | Q2 2018: $4.76 million | Q3 2018: $6.16 million | Q1 2019: $5.66 million | Q2 2019: $8.85 million | Q3 2019: $8.59 million | Q1 2020: $8.91 million | Q2 2020: $9.34 million | Q3 2020: $11.38 million | Q1 2021: $12.10 million | Q2 2021: $13.19 million | Q3 2021: $13.19 million | Q1 2022: $14.11 million | Q2 2022: $13.82 million | Q3 2022: $14.11 million | Q1 2023: $22.06 million | Q2 2023: $15.60 million | Q3 2023: $19.08 million | Q1 2024: $19.85 million | Q2 2024: $20.91 million | Q3 2024: $19.17 million | Q1 2025: $18.51 million | Q2 2025: $18.35 million | Q3 2025: $17.34 million.
- Over the full 10 years of available data (2016 to 2025), X4 Pharmaceuticals, Inc's Research And Development Expense has grown by 307.8%.
- Historical annual values: Fiscal year 2025: $72.72 million | Fiscal year 2024: $81.64 million | Fiscal year 2023: $72.02 million | Fiscal year 2022: $61.06 million | Fiscal year 2021: $50.65 million | Fiscal year 2020: $41.93 million | Fiscal year 2019: $30.16 million | Fiscal year 2018: $20.35 million | Fiscal year 2017: $17.07 million | Fiscal year 2016: $17.83 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: